hero-pipeline

UNLEASH THE POWER OF RNAa TECHNOLOGY TO TURN ON NEARLY ANY BENEFICIAL GENE

See more

Our Progress

Ractigen is an early-stage biopharmaceutical company founded on a next-generation approach to RNAa committed to bringing to market first-in-class therapeutics with a focus on cancer and debilitating genetic diseases. Ractigen is developing a rich pipeline of candidate therapeutics and actively advancing our lead compound through IND-enabling development. We implement a series of structural and chemical modifications developed internally that greatly improve the pharmacological properties of candidate drugs and maximize target gene output.

Therapeutic Area

Program

Indication

Phase

Monogenetic rare diseases

Lead discovery

RAG-06

Spinal muscular atrophy (SMA)

IND Enabling Studies

RAG-05

Acute intermittent porphyria

Lead optimisation

RAG-12

Undisclosed hepatic target

Lead discovery

Oncology

Lead discovery

RAG-01

Bladder cancer

IND Enabling Studies

RAG-07

Liver cancer

Lead optimisation

RAG-02

Immunotherapy

Lead discovery

Skin conditions

Lead discovery

RAG-11

Anti-aging

Lead discovery

RAG-04

Undisclosed

Lead discovery

Liver diseases

Lead discovery

RAG-03

Coagulation disorder

Lead discovery

RAG-10

Liver injury

Lead discovery

Others

Lead discovery

RAG-09

Sensory condition

Lead discovery

RAG-1C

Eye Condition

IND Enabling Studies

© 2017 Ractigen Therapeutics, all rights reserved

Design and Development by Digital Space